314 related articles for article (PubMed ID: 34309110)
1. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.
Liu Y; Huang N; Liao S; Rothzerg E; Yao F; Li Y; Wood D; Xu J
Cell Prolif; 2021 Sep; 54(9):e13102. PubMed ID: 34309110
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
3. Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
Zhu XZ; Mei J
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4362-70. PubMed ID: 26636524
[TBL] [Abstract][Full Text] [Related]
4. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
5. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
[TBL] [Abstract][Full Text] [Related]
7. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
8. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
9. Targeting the VEGF Pathway in Osteosarcoma.
Assi T; Watson S; Samra B; Rassy E; Le Cesne A; Italiano A; Mir O
Cells; 2021 May; 10(5):. PubMed ID: 34069999
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
11. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
[TBL] [Abstract][Full Text] [Related]
12. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
13. Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma.
Vimalraj S; Saravanan S; Raghunandhakumar S; Anuradha D
Life Sci; 2020 Sep; 256():118011. PubMed ID: 32592723
[TBL] [Abstract][Full Text] [Related]
14. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
15. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
17. [Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].
Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):624-628. PubMed ID: 32867452
[TBL] [Abstract][Full Text] [Related]
18. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin.
Kaya M; Wada T; Nagoya S; Yamashita T
J Orthop Sci; 2007 Nov; 12(6):562-7. PubMed ID: 18040639
[TBL] [Abstract][Full Text] [Related]
19. FIM-A, a phosphorus-containing sirolimus, inhibits the angiogenesis and proliferation of osteosarcomas.
Liu WN; Lin JH; Cheng YR; Zhang L; Huang J; Wu ZY; Wang FS; Xu SG; Lin WP; Lan WB; Yang GX
Oncol Res; 2013; 20(7):319-26. PubMed ID: 23879172
[TBL] [Abstract][Full Text] [Related]
20. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy.
Tanaka T; Yui Y; Naka N; Wakamatsu T; Yoshioka K; Araki N; Yoshikawa H; Itoh K
Clin Exp Metastasis; 2013 Apr; 30(4):369-79. PubMed ID: 23076771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]